One of the advantages of CAR-T therapy for the treatment of HCC is that its efficacy is not dependent on antigen presentation with major histocompatibility complex (MHC) molecules, thus addressing tumor escape due to MHC downregulation [113]. Here, HLA-C is linked to hepatocellular carcinoma.